Home/Pipeline/Teriparatide Injection

Teriparatide Injection

Osteoporosis

MarketedGeneric (Launched)

Key Facts

Indication

Osteoporosis

Phase

Marketed

Status

Generic (Launched)

Company

Amphastar Pharmaceuticals

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals' mission is to develop, manufacture, and market essential, high-barrier-to-entry pharmaceuticals, with a strategic focus on complex generics, proprietary products, and biosimilars. The company has achieved significant recognition, including an FDA Drug Shortage Assistance Award for its subsidiary, and commercial success with market-leading products like BAQSIMI® nasal glucagon. Its strategy leverages a fully integrated operational model, combining proprietary technology platforms in drug delivery with a diversified portfolio targeting endocrinology, pulmonology, and nephrology to drive sustainable growth.

View full company profile

Therapeutic Areas

Endocrinology Pulmonology Nephrology

Other Osteoporosis Drugs

Drug	Company	Phase	Status
Biosimilar to Prolia® (denosumab)	Teva	Approved/Under Review	Launched in EU, under review in US
Teriparatide	Epygen Biotech	Not Disclosed	Active
AGA2118	Angitia Biopharmaceuticals	Phase 2	Active
Teriparatide (PTH 1-34) Process	Numaferm	Commercial	Active
Recombinant Teriparatide	Paras Biopharmaceuticals Finland	Pre-clinical	Active
Stoboclo®/Osenvelt®	Celltrion	Marketed	Approved
SHR-1222	Jiangsu Hengrui Medicine	Phase III	Active
Biosimilar Denosumab	Richter Gedeon	Phase III	Active
TST002 (Blosozumab)	Transcenta Therapeutics	Phase 1	Active